Hoffmann-La Roche announced that on June 27, 2024, Health Canada granted approval of Alecensaro monotherapy as adjuvant treatment following tumour resection for patients with stage IB to IIIA anaplastic lymphoma kinase-positive non-small cell lung cancer. The company noted that Alecensaro is the first and only ALK inhibitor approved for people with ALK-positive early-stage NSCLC who have undergone surgery to remove their tumour.
The company said Alecensaro reduced the risk of disease recurrence or death by 76% in people with ALK-positive resected non-small cell lung cancer, as demonstrated in the Phase III ALINA study.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.